Nordicus Partners is a U.S.-listed holding company and business accelerator focused on early-stage Nordic life sciences companies. Nordicus scouts, acquires, and develops preclinical biotech companies from the Nordic region — primarily Denmark — with the goal of advancing them through Phase I clinical trials and then exiting via sale, partnership with a large pharma company, or standalone IPO. Nordicus currently owns two wholly-owned subsidiaries: Orocidin, which is developing QR-01, a treatment for aggressive periodontitis, and Bio-Convert, which is developing QR-02, a treatment for oral leukoplakia, a potentially pre-cancerous oral condition. Both drug candidates use a proprietary mucoadhesive oral topical formulation designed for prolonged adhesion and controlled drug release. Neither subsidiary generates revenue; both are preclinical. Nordicus funds acquisitions primarily with its own stock rather than cash, meaning dilution is the core cost of building the portfolio. The company argues its differentiation comes from combining Nordic deal sourcing with U.S. capital markets access — offering early-stage Nordic biotechs a public listing platform and management support that pure venture or private equity alternatives cannot match as efficiently. Nordicus also holds a small minority stake in Mag Mile Capital, a commercial real estate mortgage banking firm, though this is peripheral to the core life sciences business.